 |
| |
|
| ViP, The Effects
of Rofecoxib (Trade Name Vioxx) in Reducing the Risk of Prostate
Cancer |
| |
Sponsor |
| |
|
Merck |
| |
Berman Center Co-investigators |
| |
|
Site Principal Investigator: Richard Grimm, MD,
PhD
Collaborating Urologist: Philip M. Sweetser, MD
Hennepin Faculty Associates, Division of Urology |
| |
Berman Center Site Coordinator |
| |
|
Sandra
Graham,
RN
612-341-77923 |
| |
Description |
| |
|
ViP study is a double-blinded, randomized, placebo-controlled
trial evaluating the effects of rofecoxib 25mg compared with placebo
in decreasing the incidence of capsular and extracapsular prostate
cancer in men with initially elevated risk. |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
 |
 |
